Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $50.5556.

VOR has been the topic of several recent analyst reports. Wells Fargo & Company initiated coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Citigroup initiated coverage on Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright dropped their price target on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Jefferies Financial Group initiated coverage on Vor Biopharma in a research report on Monday, March 30th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st.

Vor Biopharma Stock Up 2.1%

Shares of NASDAQ VOR opened at $14.33 on Friday. The business’s 50 day moving average is $14.98 and its two-hundred day moving average is $15.14. The company has a market cap of $776.54 million, a P/E ratio of -0.04 and a beta of 1.92. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80.

Insider Activity

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director directly owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 3,002,903 shares of company stock worth $49,412,176 in the last quarter. Insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of VOR. RA Capital Management L.P. increased its position in shares of Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. increased its position in shares of Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $33,275,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $13,080,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).